Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.
Adult
Aged
Aged, 80 and over
Albumins
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cancer-Associated Fibroblasts
/ drug effects
Deoxycytidine
/ analogs & derivatives
Drug Combinations
Female
Humans
Male
Membrane Glycoproteins
/ metabolism
Middle Aged
Neoadjuvant Therapy
/ methods
Oxonic Acid
/ therapeutic use
Paclitaxel
/ therapeutic use
Pancreatic Neoplasms
/ drug therapy
Platelet Activation
/ drug effects
Platelet Glycoprotein GPIb-IX Complex
/ metabolism
Tegafur
/ therapeutic use
Gemcitabine
Pancreatic cancer stroma
cancer-associated fibroblast
extravasated platelet activation
neoadjuvant chemotherapy
podoplanin
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
25
08
2019
revised:
31
08
2019
accepted:
03
09
2019
entrez:
2
10
2019
pubmed:
2
10
2019
medline:
9
10
2019
Statut:
ppublish
Résumé
The aim of the study was to evaluate the status of extravasated platelet activation (EPA) surrounding podoplanin (PDPN)-positive cancer-associated fibroblasts (CAFs) in pancreatic cancer stroma by neoadjuvant chemotherapy. A total of 74 patients were enrolled in this study. We investigated CD42b and PDPN expression in the groups of untreated, gemcitabine (GEM) alone, GEM plus S-1 (GS) and GEM plus nab-paclitaxel (GnP). CD42b expression in surrounding CAFs was observed in 58% patients. CD42b expression was significantly correlated with PDPN expression. CD42b-positive cases were significantly lower in the group treated with GnP than in the untreated group and groups treated with GEM alone or GS. PDPN expression was reduced in the GnP group, as revealed by markedly disorganized collagen and a low density of PDPN-positive fibroblasts. There was a significantly lower CD42b expression and fewer PDPN-positive fibroblasts in the GnP group than in untreated, GEM alone, and GS groups, but there was no significant difference between the latter three groups. There is a significant association between EPA and PDPN-positive CAFs in pancreatic cancer stroma. Our data suggest that the GnP regimen decreases EPA through PDPN-positive CAF depletion.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The aim of the study was to evaluate the status of extravasated platelet activation (EPA) surrounding podoplanin (PDPN)-positive cancer-associated fibroblasts (CAFs) in pancreatic cancer stroma by neoadjuvant chemotherapy.
PATIENTS AND METHODS
METHODS
A total of 74 patients were enrolled in this study. We investigated CD42b and PDPN expression in the groups of untreated, gemcitabine (GEM) alone, GEM plus S-1 (GS) and GEM plus nab-paclitaxel (GnP).
RESULTS
RESULTS
CD42b expression in surrounding CAFs was observed in 58% patients. CD42b expression was significantly correlated with PDPN expression. CD42b-positive cases were significantly lower in the group treated with GnP than in the untreated group and groups treated with GEM alone or GS. PDPN expression was reduced in the GnP group, as revealed by markedly disorganized collagen and a low density of PDPN-positive fibroblasts. There was a significantly lower CD42b expression and fewer PDPN-positive fibroblasts in the GnP group than in untreated, GEM alone, and GS groups, but there was no significant difference between the latter three groups.
CONCLUSION
CONCLUSIONS
There is a significant association between EPA and PDPN-positive CAFs in pancreatic cancer stroma. Our data suggest that the GnP regimen decreases EPA through PDPN-positive CAF depletion.
Identifiants
pubmed: 31570451
pii: 39/10/5565
doi: 10.21873/anticanres.13750
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Drug Combinations
0
Membrane Glycoproteins
0
PDPN protein, human
0
Platelet Glycoprotein GPIb-IX Complex
0
Deoxycytidine
0W860991D6
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Paclitaxel
P88XT4IS4D
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5565-5572Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.